Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
03 Mars 2020 - 11:30PM
Business Wire
Regulatory News:
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN:
FR0004183960), a leader in digital therapeutics, and Bristol-Myers
Squibb Company (NYSE:BMY) today announced a collaboration agreement
to create and investigate digital therapeutic solutions that will
support cancer patients. Leveraging Theraxium Oncology, Voluntis’
core platform for digital therapeutics in oncology, the
collaboration will evaluate potential solutions that will support
management of patient symptoms and remote monitoring by healthcare
providers.
The goal is that the digital therapeutic, once researched and
developed, would provide patients access to a mobile application,
or app, that would support treatment and track symptoms. The app
will be developed to embed evidence-based algorithms intended to
provide patients with real-time recommendations for self-management
of symptoms related to their therapy. The parties will also
investigate how the solution could enable patients to more
effectively communicate with their health care providers, capture
and track symptoms, and receive a personalized supportive care
plan.
Paul von Autenried, Chief Information Officer, Bristol-Myers
Squibb, said, “This collaboration with Voluntis is an example of
our commitment to advance patient care with digital solutions. By
developing new technology and patient-centered initiatives such as
these, we hope to advance the standards of clinical practice.”
Pierre Leurent, CEO of Voluntis: “Bristol-Myers Squibb is a
leading innovator in oncology. We are delighted to join forces with
their talented teams to work on digital therapeutics that could
have a significant impact on the treatment experience for patients
worldwide. This collaboration is a recognition of our unique
know-how and technology, as well as an important opportunity to
bring it to scale in oncology.”
About Voluntis
Voluntis creates digital therapeutics that empower people
suffering from chronic conditions to self- manage their treatment
every day, thus improving real-world outcomes. Combining mobile and
web apps, Voluntis’ solutions deliver personalized recommendations
to the patient and the care team so that they can, for example,
adjust treatment dosage, manage side effects or monitor symptoms.
These real-time recommendations are based on digitized clinical
algorithms. Leveraging its Theraxium technology platform, Voluntis
has designed and operates multiple digital therapeutics, especially
in diabetes and oncology. Voluntis has long-standing partnerships
with leading life science companies. Based out of Boston and Paris,
France, Voluntis is a founding member of the Digital Therapeutics
Alliance. For more information, please visit: www.voluntis.com
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit BMS.com or follow on
LinkedIn, Twitter, YouTube, Facebook and Instagram.
Bristol-Myers Squibb Cautionary Statement Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the collaboration.
All statements that are not statements of historical facts are, or
may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, that are difficult to predict, may be beyond our
control and could cause our future financial results, goals, plans
and objectives to differ materially from those expressed in, or
implied by, the statements. These risks, assumptions, uncertainties
and other factors include, among others, that the expected benefits
of, and opportunities related to, the collaboration may not be
realized by Bristol-Myers Squibb or may take longer to realize than
anticipated. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that
affect Bristol-Myers Squibb’s business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for
the year ended December 31, 2019, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and Exchange Commission. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, Bristol-Myers Squibb undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303006062/en/
Voluntis Amélie Janson Head of Communications
press@voluntis.com +33 (0)1 41 38 39 20
NewCap Investor relations Louis-Victor Delouvrier
voluntis@newcap.eu +33 (0)1 44 71 94 94
NewCap Media relations Nicolas Merigeau
voluntis@newcap.eu +33 (0)1 44 71 94 98
Bristol-Myers Squibb Media: media@bms.com
609-252-3345
Investors: Tim Power, 609-252-7509, timothy.power@bms.com Nina
Goworek, 908-673-9711, ngoworek@celgene.com